Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853033 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 4
- Study locations
NCT01853033 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by AbbVie. The registered enrollment target is 19 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01853033, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ABT-122 in subjects with Rheumatoid Arthritis.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ABT-122
Study Locations (4)
Kansas
- Site Reference ID/Investigator# 108655 - Lenexa
North Carolina
- Site Reference ID/Investigator# 107115 - Raleigh
Pennsylvania
- Site Reference ID/Investigator# 118964 - Duncansville
Texas
- Site Reference ID/Investigator# 100780 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01853033
The ClinicalTrials.gov registry entry for NCT01853033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01853033 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Kansas, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01853033 about?
NCT01853033 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ABT-122 in subjects with Rheumatoid Arthritis.
What is the current status of trial NCT01853033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-07. Estimated completion is 2014-05.
What conditions does trial NCT01853033 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01853033?
The interventions under investigation include: Placebo (BIOLOGICAL), ABT-122 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01853033?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01853033 being conducted?
This trial has 4 study locations across Kansas, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.